Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
pharmaand GmbH
Revolution Medicines, Inc.
Incyte Corporation
Pfizer
Seagen Inc.
Wake Forest University Health Sciences
Gilead Sciences
Incyte Corporation
Seagen Inc.
National Institutes of Health Clinical Center (CC)
University of Kansas Medical Center
Roswell Park Cancer Institute
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc
National Institutes of Health Clinical Center (CC)